Home > Uncategorized > HOPE 3


The HOPE3 investigators published the results of the randomized clinical trial of blood pressure lowering (candesartan-hydrochlorothiazide), cholesterol lowering (with rosuvastatin) or both in patients with intermediate risk but no cardiovascular disease. The combined treatment and the cholesterol lowering therapy were associated with reduction in the primary end-point and component adverse cardiovascular events. Blood pressure alone was not associate with reduction in cardiovascular events. Subgroup analysis suggested there may be a beneficial effect in patients with baseline hypertension.


Blood Pressure Lowering and Cholesterol Lowering





Blood Pressure Lowering 


Cholesterol Lowering


Categories: Uncategorized
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: